News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Nasdaq denied Platinum Analytics' appeal and approved delisting, suspending its trading effective Sept 23, 2026, increasing liquidity and manipulation concerns.
  • Analysts recommend buying Oracle on post-Jupiter weakness: entry $135, stop $122, target $170 over a 46–180 trading-day horizon.
  • IBM called a de-risked buy after summer digest, citing 20x earnings, $13.8B FCF and a roughly 3% dividend for swing trades.
  • Ping An recommended as value entry at $13.55, citing P/B 0.33, P/E 5.35 and a 4.9% dividend for mid-term trades.
  • Kratos urged buy despite rich multiples, backed by manufacturing ramp, contract wins, and raised 2026 revenue guidance to $1.75–$1.81B.
  • Netflix pullback into the mid-$60s is framed as a tactical buying window with entry $71.15, stop $64 and target $85.
  • Q32 Bio flagged as oversold swing trade targeting ~$13.50, supported by alopecia program progress and reduced near-term cash risk.

Latest Articles

Teva Advances Anti-IL-15 Antibody TEV-’408 to Phase 2b for Vitiligo After Encouraging Phase 1b Readout

Teva Advances Anti-IL-15 Antibody TEV-’408 to Phase 2b for Vitiligo After Encouraging Phase 1b Readout

Teva Pharmaceutical Industries said it will move its investigational anti-interleukin-15 monoclonal antibody, TEV-’408, into a Phase 2b study for vitiligo in the fourth quarter of 2026. The decision follows results from an open-label Phase 1b trial in adults with active or stable non-segmental vitiligo that reported measurable gains in pigmentation…

Standard Nuclear Begins IPO Roadshow, Targets $18 to $21 Per Share

Standard Nuclear Begins IPO Roadshow, Targets $18 to $21 Per Share

Standard Nuclear, Inc. has kicked off its initial public offering roadshow offering 18,250,000 Class A shares at an expected price range of $18.00 to $21.00 per share. The company has applied to list on the New York Stock Exchange under the symbol STDN, granted underwriters a 30-day option for additional shares, and named major banks as bookrunning…

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical has entered into an agreement with Novo Nordisk to enable the evaluation of NPM-139, an ultra long-acting semaglutide implant developed using Vivani's NanoPortal technology targeting chronic weight management. The company plans to initiate a Phase 1 clinical trial comparing NPM-139 with Wegovy® injections to assess its safety, pharma…

Barclays Sees Small Earnings Impact from Potential ECB Reserve Hike

Barclays Sees Small Earnings Impact from Potential ECB Reserve Hike

Barclays analysts estimate that a hypothetical increase in the European Central Bank's minimum reserve requirement from 1% to 2% would have a modest effect on bank earnings and net interest income in 2027, but the firm regards such a policy move as unlikely. The ECB's discussions are at an early stage with a formal decision expected by autumn befor…

After Servers, Memory: Where the Next Major AI Trade Is Emerging

After Servers, Memory: Where the Next Major AI Trade Is Emerging

A rules-based AI stock selection strategy identified and captured outsized gains from two distinct corners of the AI infrastructure theme - GPU-dense servers and NAND memory. By following quantitative rankings and monthly rebalances, the strategy locked large profits in Super Micro Computer and SanDisk, then rotated capital as valuations and relati…

ZenaTech’s ZenaDrone Advances Defense Drone Portfolio with Initial IQ Sphere Prototype for Autonomous GPS-Denied Inspections, Surveillance and Reconnaissance Missions

ZenaTech’s ZenaDrone Advances Defense Drone Portfolio with Initial IQ Sphere Prototype for Autonomous GPS-Denied Inspections, Surveillance and Reconnaissance Missions

ZenaTech, Inc. announced that its subsidiary ZenaDrone is developing the IQ Sphere, a compact autonomous drone designed for defense ISR missions and commercial inspections in GPS-denied and confined environments. The platform enhances situational awareness for defense operations and critical infrastructure inspection, expanding ZenaTech's autonomou…

Glass House Brands Completes First International Hemp Sale

Glass House Brands Completes First International Hemp Sale

Glass House Brands Inc., a leading U.S. cannabis company, completed its first international sale of smokeable CBD biomass to Europe, originating from its Camarillo Farm in California. The company emphasized compliance with California regulations and positioned its production for potential federal Medicare reimbursable CBD programs. This milestone r…

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx Holdings plc announced a strategic partnership with Oberland Capital Management for an investment of up to $400 million. The deal includes up to $375 million in non-dilutive capital and $25 million in equity to support the development and commercialization of key gene therapy programs targeting radiation-induced xerostomia (AAV2-hAQP1), X-…

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics announced three late-breaking science presentations at the ESC Congress showcasing primary results from the pivotal Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy (HCM) patients. The company plans to engage regulatory authorities following positive topline results and will host an inves…

Cornerstone First Mortgage Switches to nCino's Mortgage Point of Sale to Support Its Next Phase of Growth

Cornerstone First Mortgage Switches to nCino's Mortgage Point of Sale to Support Its Next Phase of Growth

nCino, Inc. announced that Cornerstone First Mortgage has switched to using nCino's Mortgage Point of Sale platform to support its rapid growth and improve borrower experiences across its 49-state branch network. The platform's flexibility and AI-driven capabilities enable Cornerstone to streamline the loan process through digital verifications and…

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Acumen Pharmaceuticals announced it will present three studies at the Alzheimer's Association International Conference 2026, showcasing progress in its Enhanced Brain Delivery (EBD) technology developed with JCR Pharmaceuticals and patient-centric research from its ALTITUDE-AD Phase 2 trial. These studies emphasize advancements in targeting toxic a…

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Therapeutics Corp. has engaged Charles River Associates and Kaleio to evaluate commercial strategy, brand planning, and market access potential for Bria-IMT, currently in a pivotal Phase 3 trial for metastatic breast cancer. These steps show proactive preparation for potential future commercialization, subject to regulatory approval and su…

Streamex Corp. Announces 10,000,000 Share Repurchase Program

Streamex Corp. Announces 10,000,000 Share Repurchase Program

Streamex Corp., a technology and infrastructure company specializing in tokenization of commodity real-world assets, announced a board-authorized share repurchase program to buy back up to 10 million shares at prices up to $2.00 per share within the next year. The program reflects the company's confidence in its intrinsic value and long-term growth…

Israeli Airstrikes Kill Two Palestinians in Gaza, Medics Say

Israeli Airstrikes Kill Two Palestinians in Gaza, Medics Say

Israeli strikes on Tuesday killed at least two Palestinians in the Gaza Strip, Gaza health officials and medics said. One strike in the Mawasi area of Khan Younis killed a man and wounded two children, while a later strike near a tent encampment for displaced families killed another person and injured five. The Israeli military said it targeted a H…